243 related articles for article (PubMed ID: 31836424)
1. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
2. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia.
Chen HH; Lin MC; Muo CH; Yeh SY; Sung FC; Kao CH
Medicine (Baltimore); 2015 Jun; 94(24):e1013. PubMed ID: 26091447
[TBL] [Abstract][Full Text] [Related]
4. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
5. Metformin does not improve survival in patients with hepatocellular carcinoma.
Bhat M; Chaiteerakij R; Harmsen WS; Schleck CD; Yang JD; Giama NH; Therneau TM; Gores GJ; Roberts LR
World J Gastroenterol; 2014 Nov; 20(42):15750-5. PubMed ID: 25400459
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
7. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
8. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Zhang H; Gao C; Fang L; Zhao HC; Yao SK
Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049
[TBL] [Abstract][Full Text] [Related]
9. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.
Zhou YY; Zhu GQ; Liu T; Zheng JN; Cheng Z; Zou TT; Braddock M; Fu SW; Zheng MH
Sci Rep; 2016 Sep; 6():33743. PubMed ID: 27642100
[TBL] [Abstract][Full Text] [Related]
12. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
Li Q; Xu H; Sui C; Zhang H
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101781. PubMed ID: 34332136
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.
Zeng RW; Yong JN; Tan DJH; Fu CE; Lim WH; Xiao J; Chan KE; Tan C; Goh XL; Chee D; Syn N; Tan EX; Muthiah MD; Ng CH; Tamaki N; Lee SW; Kim BK; Nguyen MH; Loomba R; Huang DQ
Aliment Pharmacol Ther; 2023 Mar; 57(6):600-609. PubMed ID: 36625733
[TBL] [Abstract][Full Text] [Related]
14. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.
Simon TG; Chan AT
Clin Liver Dis; 2020 Nov; 24(4):549-576. PubMed ID: 33012445
[TBL] [Abstract][Full Text] [Related]
15. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.
Zhang ZJ; Zheng ZJ; Shi R; Su Q; Jiang Q; Kip KE
J Clin Endocrinol Metab; 2012 Jul; 97(7):2347-53. PubMed ID: 22523334
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Harris K; Smith L
Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
[TBL] [Abstract][Full Text] [Related]
17. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
Chen HP; Shieh JJ; Chang CC; Chen TT; Lin JT; Wu MS; Lin JH; Wu CY
Gut; 2013 Apr; 62(4):606-15. PubMed ID: 22773548
[TBL] [Abstract][Full Text] [Related]
18. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.
Bosetti C; Franchi M; Nicotra F; Asciutto R; Merlino L; La Vecchia C; Corrao G
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):771-8. PubMed ID: 26013675
[TBL] [Abstract][Full Text] [Related]
19. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
20. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
